Our latest report yesterday revealed that only 5 out of 300 current type 1 diabetes trials currently meet the JDCA definition for a cure. Although this shows how little money donated towards cure fundraisers is actually going to that purpose, we can also focus on the potential of these five trials that we cave identified to bring about the much-awaited cure.
The trials are:
- DIABECELL3
- Monolayer Cellular Device (“MCD”)4
- ATG/GCSF5
- Diamyd/Sitagliptin/Lansoprazole (“D/S/L”)6
- Sitagliptin/Lansoprazole (“S/L”)7
– In the first two, DIABECELL and MCD, insulin-producing islets are enclosed within a protective sheath or device and then implanted into an individual’s abdomen.This involves a minor surgical procedure. The islets’ protective covering shields them from an autoimmune attack, yet allows the secretion of insulin to regulate an individual’s blood sugar levels.
– The other three, ATG/GCSF, D/S/L and S/L, utilize a combination of
drugs that are designed to stop the autoimmune attack and to stimulate growth of beta cells.
Which trial is in the most advanced stage? Currently, DIABECELL is in Phase 2 and has already been approved in Russia. Make sure to read the report in full for more information on the trials.
Since all five trials are currently at the clinical stage, they all have the potential to meet JDCA’s 2025 target and develop a Practical Cure cure for type 1 diabetes. Of course, we are still far from proclaiming anything with certainty, but we must keep hoping and continue pushing for a cure. Work is being done, and progress is being made – but it’s up to us not to allow the momentum to slip away.
– Stoyan
Advertisement
